Your browser doesn't support javascript.
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.
Ip, Andrew; Ahn, Jaeil; Zhou, Yizhao; Goy, Andre H; Hansen, Eric; Pecora, Andrew L; Sinclaire, Brittany A; Bednarz, Urszula; Marafelias, Michael; Sawczuk, Ihor S; Underwood, Joseph P; Walker, David M; Prasad, Rajiv; Sweeney, Robert L; Ponce, Marie G; La Capra, Samuel; Cunningham, Frank J; Calise, Arthur G; Pulver, Bradley L; Ruocco, Dominic; Mojares, Greggory E; Eagan, Michael P; Ziontz, Kristy L; Mastrokyriakos, Paul; Goldberg, Stuart L.
  • Ip A; Division of Outcomes and Value Research, John Theurer Cancer Center at Hackensack University Medical Center, 92 Second Street, Hackensack, NJ, 07601, USA. Andrew.Ip@hackensackmeridian.org.
  • Ahn J; Hackensack Meridian Health, Hackensack, NJ, USA. Andrew.Ip@hackensackmeridian.org.
  • Zhou Y; Hackensack Meridian School of Medicine at Seton Hall University, Nutley, NJ, USA. Andrew.Ip@hackensackmeridian.org.
  • Goy AH; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, D.C., USA.
  • Hansen E; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, D.C., USA.
  • Pecora AL; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
  • Sinclaire BA; COTA, Boston, MA, USA.
  • Bednarz U; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
  • Marafelias M; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
  • Sawczuk IS; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
  • Underwood JP; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
  • Walker DM; Hackensack Meridian Health, Hackensack, NJ, USA.
  • Prasad R; Hackensack Meridian School of Medicine at Seton Hall University, Nutley, NJ, USA.
  • Sweeney RL; Hackensack University Medical Center, Hackensack, NJ, USA.
  • Ponce MG; Hackensack University Medical Center, Hackensack, NJ, USA.
  • La Capra S; Bayshore Medical Center, Holmdel, NJ, USA.
  • Cunningham FJ; Jersey Shore University Medical Center, Neptune City, NJ, USA.
  • Calise AG; Jersey Shore University Medical Center, Neptune City, NJ, USA.
  • Pulver BL; JFK Medical Center, Edison, NJ, USA.
  • Ruocco D; JFK Medical Center, Edison, NJ, USA.
  • Mojares GE; Hackensack Meridian Mountainside Medical Center, Montclair, NJ, USA.
  • Eagan MP; Ocean Medical Center, Brick, NJ, USA.
  • Ziontz KL; Palisades Medical Center, North Bergen, NJ, USA.
  • Mastrokyriakos P; Pascack Valley Medical Center, Westwood, NJ, USA.
  • Goldberg SL; Raritan Bay Medical Center, Old Bridge, NJ, USA.
BMC Infect Dis ; 21(1): 72, 2021 Jan 14.
Article in English | MEDLINE | ID: covidwho-1067195
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

BACKGROUND:

Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting.

METHODS:

We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching.

RESULTS:

Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available.

CONCLUSIONS:

In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: S12879-021-05773-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: S12879-021-05773-w